Your session is about to expire
← Back to Search
Dapagliflozin for Coronary Artery Disease (SMILE Trial)
SMILE Trial Summary
This trial will test a drug to improve blood flow in women with ischemic heart disease. Participants will take the drug or placebo for 12 weeks and have scans to measure heart blood flow.
SMILE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSMILE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 30 Patients • NCT03006471SMILE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a serious heart valve condition.I often feel faint due to low blood pressure below 95 mmHg.I was referred for a heart check-up due to suspected blockage signs within the last 2 years.I have type 2 diabetes and have had diabetic ketoacidosis.My kidney function is at a safe level for the trial.My kidney disease is severe, unstable, or getting worse quickly.I have not had a stroke or brain bleed in the last 6 months.I am currently receiving treatment for an active cancer.I have had multiple urinary or kidney infections.My heart's major arteries are not significantly blocked.My doctor expects I have less than 3 years to live due to a non-heart related condition.I have Type 1 diabetes.I have a history of heart failure, severe lung or liver disease.I have a heart condition with weak pumping or thickened heart muscle.I had a heart attack or severe chest pain in the last 30 days.
- Group 1: Placebo
- Group 2: Dapagliflozin
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What have been the effects of Dapagliflozin on patient health?
"Our team at Power has assessed the safety of Dapagliflozin to be a 1 due to it being in a Phase 1 clinical trial, wherein limited data is available regarding its efficacy and safety."
Can I be accepted as a participant in this medical trial?
"This medical trial is accepting 40 participants with myocardial ischemia, who are aged between 18 and 99."
Does this trial include elderly individuals or is there an age limit?
"This clinical trial is open to adults aged 18-99. For those who are under the legal age of adulthood, there are 46 studies that may be applicable and 882 for seniors aged 65+."
Are there still enrollments available for this clinical research?
"Correct. According to clinicaltrials.gov, this medical study is now open for recruitment and was initially posted on May 24th 2023. 40 participants are needed from 1 site with the last edit occuring on May 8th 2023."
What is the magnitude of participants involved in this research?
"Affirmative, the information hosted on clinicaltrials.gov declares that recruitment for this medical trial is happening now. The study was launched on May 24th 2023 and last updated a few weeks later on May 8th. 40 individuals are being sought from 1 distinct location to take part in the experiment."
Share this study with friends
Copy Link
Messenger